Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure

Trial Profile

Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Acronyms PRESERVED-HF
  • Most Recent Events

    • 01 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 03 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top